With No mRNA Vaccines In Sight, Frustration Grows In China
More Jabs Won't Solve Low Efficacy Issue
A top virologist and prominent Chinese researcher sounds alarm over reluctance to clear mRNA vaccines amid regional outbreaks and the government rollout of inactivated virus-based booster shots without real-word evidence.
You may also be interested in...
The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.
China's main pharma hub of Shanghai reported sector output has plunged by more than half due in large part to the prolonged lockdown, while 58% of surveyed foreign companies in China across all industries project declining revenue.